IP Verse

Combination Of Vaccination And Inhibition Of The Pd-1 Pathway - EP2958588

The patent EP2958588 was granted to Curevac on Aug 23, 2017. The application was originally filed on Feb 21, 2014 under application number EP14706481A. The patent is currently recorded with a legal status of "Revoked".

EP2958588

CUREVAC
Application Number
EP14706481A
Filing Date
Feb 21, 2014
Status
Revoked
May 24, 2024
Grant Date
Aug 23, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ETHERNA IMMUNOTHERAPIESMay 23, 2018ARNOLD & SIEDSMAADMISSIBLE
MERCK SHARP & DOHMEMay 23, 2018KILBURN & STRODEADMISSIBLE
STRAWMANMay 23, 2018VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE
MODERNAMay 22, 2018HOFFMANN EITLEADMISSIBLE
SCHNAPPAUFMay 22, 2018-ADMISSIBLE

Patent Citations (32) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2010055102
DESCRIPTIONUS4816567
DESCRIPTIONWO2008011344
DESCRIPTIONWO2012062218
INTERNATIONAL-SEARCH-REPORTUS2010055102
INTERNATIONAL-SEARCH-REPORTWO2008011344
INTERNATIONAL-SEARCH-REPORTWO2008156712
INTERNATIONAL-SEARCH-REPORTWO2010063011
INTERNATIONAL-SEARCH-REPORTWO2012062218
OPPOSITIONEP1392341
OPPOSITIONEP1604688
OPPOSITIONUS2008267873
OPPOSITIONUS2010035973
OPPOSITIONUS2010040614
OPPOSITIONUS2010055102
OPPOSITIONUS8008449
OPPOSITIONUS8168757
OPPOSITIONUS8217016
OPPOSITIONWO2004004743
OPPOSITIONWO2006044923
OPPOSITIONWO2008011344
OPPOSITIONWO2008083174
OPPOSITIONWO2008083949
OPPOSITIONWO2008085562
OPPOSITIONWO2008156712
OPPOSITIONWO2009114335
OPPOSITIONWO2010037408
OPPOSITIONWO2010063011
OPPOSITIONWO2011143656
OPPOSITIONWO2012006634
OPPOSITIONWO2012062218
OPPOSITIONWO2013143683

Non-Patent Literature (NPL) Citations (63) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- AGARWAL, N. et al., "Development of novel immune interventions for genito-urinary cancers", Cancer Vaccines: From Research to Clinical Practice, (20110000), pages 25 - 43, XP055492086-
OPPOSITION- Anonymous, "A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages Ill/IV Melanoma (Study NCT01176461)", American Society of Clinical Oncology ASCO, (20120128), pages 1 - 10, XP055493148-
OPPOSITION- BERENBAUM, "Synergy, additivism and antagonism in immunosuppresion", Clin Exp Immunol, (19770000), vol. 28, pages 1 - 18, XP055246276-
OPPOSITION- FOTIN-MLECZEK et al., "Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity", J Immunother, (20110000), vol. 34, pages 1 - 15, XP002665988-
OPPOSITION- FOTIN-MLECZEK et al., "Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity", Journal of Immunotherapy, (20110000), vol. 34, pages 1 - 15, XP002665988-
OPPOSITION- HOERR, "Abstract OP 57, Stabilized Messenger RNA (RNActive?) as a Tool for Innovative Gene Delivery , presented at the BioStar 2006 2nd International Congress on Regenerative Biology and ICBN 2006 2nd International Congress on Bio-Nano-Interface held", Tissue Engineering, (20061009), vol. 13, pages 886 - 887, XP009125215-
OPPOSITION- MACKENSEN, A., "Peptide and RNA-based vaccines for the treatment of cancer", Onkologie, (20110930), vol. 34, page 202, XP055493075-
OPPOSITION- "Multiple Class I Peptides & montanide ISA 51 VG w Escalating Doses of Anti-PD-1 Antibody BMS936558 (Study NCT01176474)", ClinicalTrials.gov, (20130000), XP055493156-
OPPOSITION- ROSENBLATT, JACALYN et al., "CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma", Blood, (20090000), XP055493169-
OPPOSITION- SOARES, KEVIN C. et al., "Abstract PR9:Granulocyte macrophage colony stimulating factor (GM-CSF) pancreas tumor vaccine in combination with blockade of PD-1 in a preclinical model of pancreatic cancer", Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances, Miami, FL. Philadelphia (PA, vol. 73, no. 1, XP055493192-
OPPOSITION- VOGELZANG, NICHOLAS J. et al., "3 Development of novel immune interventions for genito-urinary cancers", VOGELZANG, NICHOLAS J. et al., Adrian Bot, Mihail Obrocea, Francesco M. Marincola, Cancer Vaccines, CRC Press, (20111123), pages 25 - 43, XP055492086-
OPPOSITION- WEIDE, B. et al., "Plasmid DNA-and messenger RNA-based anti-cancer vaccination", Immunology lette rs, (20080000), vol. 115, no. 1, pages 33 - 42, XP026863354-
OPPOSITION- YAO et al., "Advances in targeting cell surface signalling molecules for immune modulation", NIH Public Access Author Manuscript, (20130201), vol. 12, no. 2, pages 1 - 33, XP055493089-
OPPOSITION- MARTINON et al., "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA", European Journal of Immunology, (19930000), vol. 23, pages 1719 - 1722, XP000618955
OPPOSITION- SIERRO et al., "Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity", European Journal of Immunology, vol. 41, no. 8, pages 1521 - 4141, XP002716011
OPPOSITION- SIERRO, SOPHIE R. et al., "Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity", European journal of immunolo gy, (20110800), vol. 41, no. 8, pages 2217 - 2228, XP055053701
OPPOSITION- MKRTICHYAN et al., "Anti-PD-1 synergises with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms", Eur J Immunol., (20110000), vol. 41, no. 10, pages 2977 - 2986, XP055497998
OPPOSITION- MKRTICHYAN et al., "Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms", European Journal of Immunology, (20110000), vol. 41, pages 2977 - 2986, XP055497998
OPPOSITION- FOTIN-MLECZEK et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", J Gene Med, (20120600), vol. 14, no. 6, pages 428 - 439, XP002716014
OPPOSITION- FOTIN-MLECZEK et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", Journal of Gene Medicine, (20120000), vol. 14, pages 428 - 439, XP002716014
OPPOSITION- FOTIN-MLECZEK et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", Journal of Gene Medicine, vol. 14, no. 6, pages 428 - 439, XP002716014
OPPOSITION- FOTIN-MLECZEK, MARIOLA et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", The journal of gene medicine, (20120000), vol. 14, no. 6, pages 428 - 439, XP002716014
OPPOSITION- FOTIN-MLECZEK, M. et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", The journal of gene medicine, (20120000), vol. 14, no. 6, pages 428 - 439, XP002719717
OPPOSITION- STRAIN, DANIEL, "Crushing Cancer's Defenses: Vaccine approval offers hope while other armies muster", Science News, (20110507), vol. 179, no. 10, pages 20 - 23, XP055493182
OPPOSITION- MONIE et al., "Modification of Dendritic Cells to Enhance Cancer Vaccine Potency", Targeted Cancer Immune Therapy, New York NY, (20090000), pages 133 - 157, XP055493069
OPPOSITION- TOPALIAN et al., "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti- tumor immunity", Current Opinion in Immunology, (20120000), vol. 24, pages 207 - 212, XP002714810
OPPOSITION- TOPALIAN et al., "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity", Curr Opin Immunol., (20120109), vol. 24, no. 2, pages 207 - 212, XP002714810
OPPOSITION- ULMER et al., "RNA-based vaccines", Vaccine, (20120428), vol. 30, no. 30, pages 4414 - 4418, XP028520925
OPPOSITION- OMORI, RISA et al., "Effects of interferon-a transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors", Cancer gene therapy, (20120900), vol. 19, no. 9, pages 637 - 643, XP055299990
OPPOSITION- DAI et al., "PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell -directed lentiviral vaccines", Molecular Therapy: The Journal of the American Society of Gene Therapy, vol. 20, no. 9, pages 1800 - 1809, XP002716012
OPPOSITION- PARDOLL, DREW M., "The blockade of immune checkpoints in cancer immunotherapy", Nature Reviews Cancer, (20120400), vol. 12, no. 4, pages 252 - 264, XP055415943
OPPOSITION- PARDOLL et al., "The blockade of immune checkpoints in cancer immunotherapy", Nature Reviews Cancer, (20120322), vol. 12, pages 252 - 264, XP055150744
OPPOSITION- PARDOLL, "The blockade of immune checkpoints in cancer immunotherapy", Nature Reviews Cancer, (20120000), vol. 12, pages 252 - 264, XP055150744
OPPOSITION- WEBER et al., "Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade", Seminars in Oncology, (20101000), vol. 37, no. 5, pages 430 - 439, XP009177527
OPPOSITION- WEBER, "Immune checkpoint proteins: a new therapeutic paradigms the cancer - preclinical background: CTLA-4 and PD-1 blockade", Seminars in Oncology, (20100000), vol. 37, no. 5, pages 430 - 439, XP009177527
OPPOSITION- WEBER, JEFFREY, "Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade", Seminars in oncology, (20101000), vol. 37, no. 5, pages 430 - 439, XP009177527
OPPOSITION- WEBER, J., "Immune checkpoint proteins: a new therapeutic paradigm for cancer - preclinical background: CTLA-4 and PD-1 blockade", Seminars in oncology, (20101000), vol. 37, no. 5, pages 430 - 439, XP009177527
OPPOSITION- CURRAN et al., "PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors", Proc Natl Acad Sci U S A., (20100216), vol. 107, no. 9, pages 4275 - 4278, XP055067204
OPPOSITION- CURRAN et al., "PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumours", PNAS, (20100000), vol. 107, no. 9, pages 4275 - 4280, XP055067204
OPPOSITION- HA et al., "Enhancing therapeutic vaccination by blocking PD-1 - mediated inhibitory signals during chronic infection", J Exp Med., (20080317), vol. 205, no. 3, pages 543 - 555, XP007910673
OPPOSITION- HA, S. J. et al., "Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection", Journal of Experimental Medicine, (20080000), vol. 205, no. 3, pages 543 - 555, XP007910673
OPPOSITION- WONG, RAYMOND M. et al., "Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs", International Immunology, (20070000), vol. 19, no. 10, pages 1223 - 1234, XP009105472
OPPOSITION- SONG et al., "Enhancement of Vaccine-induced Primary and Memory CD 8+ T- cell Responses by Soluble PD-1", Journal of Immunotherapy, (20110000), vol. 34, pages 297 - 306, XP055498003
OPPOSITION- ROSENBLATT et al., "PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine", NIH Public Access Author Manuscript, (20110601), vol. 34, no. 5, pages 1 - 20, XP055493200
OPPOSITION- ROSENBLATT J et al., "PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T- cell responses to autologous dendritic cell /myeloma fusion vaccine", NIH Public Access Author Manuscript, (20110000), vol. 34, pages 1 - 20, XP055493200
OPPOSITION- POSTOW et al., "Beyond Cancer Vaccines: A Reason for Future Optimism with lmmunomodulatory Therapy", NIH Public Access Author Manuscript, (20110900), vol. 17, no. 5, pages 1 - 13, XP055510153
OPPOSITION- SLINGLUFF, "The present and future of peptide vaccines for cancer...", Cancer J, (20110000), vol. 17, no. 5, pages 343 - 350, XP009160448
OPPOSITION- DURASWAIMY et al., "Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors", Cancer Res., (20130430), vol. 73, no. 12, pages 3591 - 603, XP055218335
OPPOSITION- LI, BETTY et al., "Anti-programmed death-1 synergizes with granulocyte macrophage colony- stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors", Clinical Cancer Research, (20090301), vol. 15, no. 5, pages 1623 - 1634, XP055166457
OPPOSITION- LI et al., "Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors", Clin Cancer Res, (20090210), vol. 15, no. 5, pages 1623 - 1634, XP055166457
OPPOSITION- LI et al., "Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors", Clin Cancer Res., vol. 15, no. 5, pages 1623 - 1634, XP055166457
OPPOSITION- LI et al., "Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors", Clinical Cancer Research, (20090000), vol. 15, no. 5, pages 1623 - 1634, XP055166457
OPPOSITION- MELERO I et al., "Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination", Clinical Cancer Research, (20090301), vol. 15, no. 5, pages 1507 - 1509, XP055492075
OPPOSITION- MELERO, IGNACIO et al., "Palettes of vaccines and immunostimulatory monoclonal antibodies for combination", Clinical Cancer Research, (20090000), vol. 15, no. 5, pages 1507 - 1509, XP055493136
OPPOSITION- BRAHMER et al., "Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer", Cancer Immunol Res., (20130722), vol. 1, no. 2, pages 85 - 91, XP055198615
OPPOSITION- VANHAM et al., "Can immunotherapy be useful as a ''functional cure'' for infection with Human Immunodeficiency Virus-1?", Retrovirology, (20120000), vol. 9, no. 1, pages 1 - 21, XP021107722
OPPOSITION- PASCOLO, "Vaccination with Messenger RNA", Methods in Molecular Medicine, (20060000), vol. 127, pages 23 - 40, XP009117840
OPPOSITION- ZHOU et al., "Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization", Journal of Immunology, (20100000), vol. 185, no. 9, pages 5082 - 5092, XP055497999
OPPOSITION- ROSSI et al., "Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity", J Immunol, (20050801), vol. 175, pages 1373 - 1381, XP055510144
OPPOSITION- ZITVOGEL et al., "Targeting PD-1/PD-L1 interactions for cancer immunotherapy", Oncoimmunology, vol. 1, no. 8, pages 1223 - 1225, XP002716013
OPPOSITION- ZITVOGEL, LAURENCE et al., "Targeting PD-1/PD-L1 interactions for cancer immunotherapy", Oncoimmunology, (20121100), vol. 1, no. 8, pages 1223 - 1225, XP002716013
OPPOSITION- SCHLAKE et al., "Developing mRNA-vaccine technologies", RNA biology, (20120000), vol. 9, no. 11, pages 1319 - 1330, XP055098782
OPPOSITION- ICLOZAN et al., "Recent advances in immunotherapy of lung cancer", Journal of Lung Cancer, (20120000), vol. 11, no. 1, pages 1 - 11, XP055493027

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents